HEMOPHILIA B
Clinical trials for HEMOPHILIA B explained in plain language.
Never miss a new study
Get alerted when new HEMOPHILIA B trials appear
Sign up with your email to follow new studies for HEMOPHILIA B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Time gene therapy could free hemophilia b patients from frequent infusions
Disease control OngoingThis study tests a one-time gene therapy for adult men with moderate to severe hemophilia B, a bleeding disorder caused by a missing or faulty Factor IX gene. The therapy delivers a working copy of the gene to help the body produce its own clotting factor. Researchers will track …
Matched conditions: HEMOPHILIA B
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New hope for hemophilia b: Long-Lasting clotting factor under study
Disease control OngoingThis study tests a new drug called rIX-FP, which is a long-lasting clotting factor, in 23 Chinese men with hemophilia B. The goal is to see how well it prevents and treats bleeding episodes when given regularly. Participants receive the drug as a routine shot to keep their clotti…
Matched conditions: HEMOPHILIA B
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
One-Shot gene therapy aims to stop bleeding in hemophilia b patients
Disease control OngoingThis study tests a single-dose gene therapy called BBM-H901 in 32 adults with severe hemophilia B. The treatment uses a harmless virus to deliver a working gene that helps the body produce its own clotting factor, potentially reducing or preventing bleeding episodes. Researchers …
Matched conditions: HEMOPHILIA B
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
Gene therapy breakthrough: hemophilia b patients may need fewer treatments
Disease control OngoingThis study looks at the long-term safety and effectiveness of a gene therapy (PF-06838435) for people with severe hemophilia B, a bleeding disorder. It follows patients who already received the therapy and also tests a higher dose in new participants. The goal is to see if the tr…
Matched conditions: HEMOPHILIA B
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
One-Time gene shot could tame hemophilia b bleeding
Disease control OngoingThis study tests a single intravenous dose of gene therapy (AskBio009) in up to 30 adults with hemophilia B, a bleeding disorder. The therapy delivers a working copy of the factor IX gene to help the body produce its own clotting factor. The goal is to reduce the frequency and se…
Matched conditions: HEMOPHILIA B
Phase: PHASE1, PHASE2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated May 04, 2026 16:30 UTC
-
No new drug: study tracks bleeding in hemophilia b patients
Knowledge-focused OngoingThis study watches 11 males with Hemophilia B who already get regular factor IX treatment to prevent bleeding. Researchers will track bleeding events, joint health, and quality of life for 6 months. No new drug is tested; the goal is to gather information for future studies.
Matched conditions: HEMOPHILIA B
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated May 06, 2026 16:01 UTC